Asim K Debnath
Head
Complement Biology
Complement Biology, New York Blood Center
United States of America
Biography
"Dr. Debnath's research focus is to identify new antiviral drugs by state-of-the art drug design methods. Ongoing projects include: Identification of small molecule entry inhibitors that target specifically HIV-1 envelope glycoprotein gp120 and disrupt it’s binding to the T-cell surface receptor CD4. Identification of the best combination of latency reversing agents (LRAs) to facilitate eradication of HIV-1 from virus reservoirs by drugs, antibody drug conjugates (ADC) or immune system. This is expected to help in achieving functional cure of HIV-1. Identification of novel agents for pathogen inactivation of blood products."
Research Interest
Virology
Publications
-
Debnath AK, Lopez de Compadre RL, Debnath G, Shusterman AJ, Hansch C (1991) Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity. J Med Chem 34: 786-797.
-
Lopez de Compadre RL, Debnath AK, Shusterman AJ, Hansch C (1990) LUMO energies and hydrophobicity as determinants of mutagenicity by nitroaromatic compounds in Salmonella typhimurium. Environ Mol Mutagen 15: 44-55.
-
Shusterman AJ, Debnath AK, Hansch C, Horn GW, Fronczek FR, et al. (1989) Mutagenicity of dimethyl heteroaromatic triazenes in the Ames test: the role of hydrophobicity and electronic effects. Mol Pharmacol 36: 939-944.
